Summary
The in vivo effect of forskolin on insulin release, blood glucose and intravenous glucose tolerance test has been studied in the rat. In addition in vitro experiments on the effect of forskolin on islet cAMP and insulin release have been performed for comparison purposes.
In batch incubated islets forskolin increased cAMP levels concentration dependently, the EC50 being approximately 25 μM. The maximal effect occurred after 5 min. In the presence of 2.8 mM glucose 10μM forskolin did not stimulate insulin release; however, it potentiated both phase of 11.1 mM glucose induced insulin secretion.
I. v. administration of 1.5 mg/kg of forskolin increased blood glocose levels in rats, which was associated with significant elevation of serum insulin. During an i. v. glucose tolerance test forskolin potentiated the insulin releasing capacity of glucose but did not significantly affect blood glucose levels. It is conceivable that cAMP per se does not initiate but rather amplifies insulin release by glucose. Since the synergistic effect of forskolin and glucose on insulin release in vivo is not associated with increased elimination rate it is possible that forskolin exhibits additional effects which counteract the glucose lowering action of insulin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bihler J, Sarvh PC, Sloan JG (1978) Dual effect of adrenalin on sugar transport in rat diaphragm muscle. Biochim Biophys Acta 510:349–360
Daly JW, Padgett W, Seamon KB (1982) Activation of cyclic AMP-generating systems in brain membranes and slices by the diterpen forskolin: aumentation of receptor-mediated responses. J Neurochem 38:532–544
Darfler FJ, Mahan LC, Koachman AM, Insel PA (1982) Stimulation by forskolin of intact S49 lymphoma cells involves the nucleotide regulatory protein of adenylate cyclase. J Biol Chem 257:11901–11907
Exton JH, Robinson GA, Sutherland EW, Park CR (1971) Studies on the role of adenosine 3′, 5′-monophosphate in the hepatic actions of glucagon and catecholamines. J Biol Chem 246:6166–6177
Harper JF, Brooker GJ (1975) Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2′O acetylation by acetic anhydride in aqueous solution. J Cycl Nucl Res 1:207–218
Hellman B, Idahl L-A, Lernmark A, Täljedahl I-B (1974) The pancreatic β-cell recognition of insulin secretagogues: does cyclic AMP mediate the effect of glucose. Proc Natl Acad Sci USA 71:3405–3409
Huang R-D, Smith MF, Zahler WL (1982) Inhibition of forskolin activated adenylate cyclase by ethanol and other solvents. J Cycl Nucl Res 8:385–394
Insel PA, Stengel D, Ferry N, Hanoune J (1982) Regulation of adenylate cyclase of human platelet membranes by forskolin. J Biol Chem 257:7485–7490
Kashiwagi A, Hueckstaedt TP, Foley JE (1983) The regulation of glucose transport by cAMP stimulatory via three different mechanisms in rat and human adipocytes. J Biol Chem 158:13685–13692
Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39
Litosch I, Hudson TH, Mills J, Li S, Fain JN (1982) Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adepocytes. Mol Pharmacol 22:109–115
Metzger H, Linder E (1981a) Foskolin — a novel ademylate-cyclase-acitivator. IRCS Med Sci 9:99
Metzger H, Linder E (1981b) The positive inotropic acting forskolin, a potent adenylatecyclase activator. Arzneim-Forsch/Drug Res 31:1248–1250
Robberecht P, Wallbroeck M, Chatelain P, Camus J-C, Christophe J (1983) Inhibition of forskolin-stimulated cardiac adenylate cyclase activity by short-chain alcohols. FEBS Letters 154:205–208
Seamon KB, Daly JW (1981a) Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 256:9799–9801
Seamon KB, Daly JW (1981b) Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J Cyclic Nucl Res 7:201–224
Seamon KB, Padgett W, Daly JW (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and intract cells. Proc Natl Acad Sci USA 78:3363–3367
Sharp GWG (1979) The adenylate-cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin release. Diabetologia 16:287–296
Siegl AM, Daly JW, Smith JB (1982) Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol 21:680–687
Soeldner JS, Slone D (1965) Critical variables in the radioimmunoassay of seruminsulin using the double antibody technique. Diabetes 14:771–779
Stengel D, Guenet L, Desmier M, Insel P, Hanoune J (1982) Forskolin requires more than the catalytic unit to activate adenylate cyclase. Mol Cell Endocrinol 28:681–690
Watson EL, Dowd FJ (1983) Forskolin: effects on mouse parotid gland function. Biochem Biophys Res Comm 111:21–27
Wiedenkeller DE, Sharp GWG (1983) Effects of forskolin on insulin release and cyclic AMP content in rat pancreatic islets. Endocrinology 113:2311–2313
Wollheim CB, Sharp GWG (1981) Regulation of insulin release by calcium. Physiol Rev 61:914–973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ammon, H.P.T., Müller, A.B. Effect of forskolin on islet cyclic AMP, insulin secretion, blood glucose and intravenous glucose tolerance in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 326, 364–367 (1984). https://doi.org/10.1007/BF00501444
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00501444